AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 613
- Registration Number
- NCT00628862
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux
Phase 4
Completed
- Conditions
- Chronic Posterior Laryngitis (CPL)
- Interventions
- Drug: EsomeprazoleDrug: Placebo
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00628667
Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: AZD4818Drug: Placebo
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00629239
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Aclidinium/Formoterol Fixed Combination Dose Finding Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 808
- Registration Number
- NCT00626522
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
Phase 3
Completed
- Conditions
- Symptomatic Gastroesophageal Reflux Disease (sGERD)
- Interventions
- Drug: EsomeprazoleDrug: Matching placebo
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00626535
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
Phase 3
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Drug: PalceboDrug: ZD4054
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2577
- Registration Number
- NCT00626548
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00626262
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00625495
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
Phase 4
Completed
- Conditions
- HeartburnUpper Abdominal PainNauseaAcid Regurgitation
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00625274
Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 165
- Registration Number
- NCT00623519
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
© Copyright 2025. All Rights Reserved by MedPath